+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Almirall SA (ALM) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 62 Pages
  • May 2023
  • GlobalData
  • Almirall, S.A.
  • ID: 4308187
Almirall SA (ALM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Almirall SA (Almirall) is a specialty pharmaceutical company that researches, develops, manufactures, and commercializes proprietary medicines and licensed products. The company’s major area of focus is dermatology covering psoriasis, eczema, psoriasis, oncodermatology, onychomicosis, actinic keratosis, acne, and other skin infections. It also develops products for autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. The company also works together with small and medium-sized companies and healthcare professionals to develop medical solutions and provide them to patients. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.

Almirall SA Key Recent Developments

  • Feb 20, 2023: Almirall’s Full-Year 2022 Results
  • Nov 28, 2022: Almirall to take part in FACILITATE project to enable trial data usage
  • Nov 08, 2022: Almirall opens a new subsidiary for the Czech Republic and Slovakia
  • May 09, 2022: Almirall Announce First Quarter 2022 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Almirall SA - Key Facts
  • Almirall SA - Key Employees
  • Almirall SA - Key Employee Biographies
  • Almirall SA - Major Products and Services
  • Almirall SA - History
  • Almirall SA - Company Statement
  • Almirall SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Almirall SA - Business Description
  • Business Segment: Corporate management and results not allocated to other segments
  • Performance
  • Business Segment: Dermatology in the US
  • Performance
  • Business Segment: Sales through licensees
  • Performance
  • Business Segment: Sales through own network
  • Performance
  • Geographical Segment: America, Asia and Africa
  • Performance
  • Geographical Segment: Corporate Management and Revenue not Allocated to Other Segments
  • Performance
  • Geographical Segment: Europe and Middle East
  • Performance
  • Geographical Segment: Spain
  • Performance
  • R&D Overview
  • Almirall SA - Corporate Strategy
  • Almirall SA - SWOT Analysis
  • SWOT Analysis - Overview
  • Almirall SA - Strengths
  • Almirall SA - Weaknesses
  • Almirall SA - Opportunities
  • Almirall SA - Threats
  • Almirall SA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Almirall SA, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Almirall SA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Feb 20, 2023: Almirall’s Full-Year 2022 Results
  • Nov 28, 2022: Almirall to take part in FACILITATE project to enable trial data usage
  • Nov 08, 2022: Almirall opens a new subsidiary for the Czech Republic and Slovakia
  • May 09, 2022: Almirall Announce First Quarter 2022 Financial Results
  • May 06, 2022: Carlos Gallardo assumes the Presidency of Almirall
  • Feb 21, 2022: Dr. Jorge Gallardo Ballart announces his intention to retire from his positions of President of the Board of Directors and Board member of Almirall
  • Feb 21, 2022: Almirall Announce Financial Results for 2021
  • Jan 21, 2022: Boryung to market Almirall's spray-type hair loss treatment in Korea
  • Jan 18, 2022: IRB Barcelona and Almirall announce a research collaboration to discover novel molecular glue therapeutics for severe skin diseases
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Almirall SA, Key Facts
  • Almirall SA, Key Employees
  • Almirall SA, Key Employee Biographies
  • Almirall SA, Major Products and Services
  • Almirall SA, History
  • Almirall SA, Subsidiaries
  • Almirall SA, Key Competitors
  • Almirall SA, Ratios based on current share price
  • Almirall SA, Annual Ratios
  • Almirall SA, Interim Ratios
  • Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Almirall SA, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Almirall SA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Almirall SA, Performance Chart (2018 - 2022)
  • Almirall SA, Ratio Charts
  • Almirall SA, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Almirall SA, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Sucampo Pharmaceuticals Inc
  • Neoleukin Therapeutics Inc
  • Laboratorio CIFGA SA
  • Biosearch SA
  • ALK-Abello AS
  • Laboratorios Richmond SACIF
  • GSK plc
  • Esteve Pharmaceuticals SA
  • Laboratorios Farmaceuticos Rovi SA
  • Faes Farma SA
  • Neoleukin Therapeutics Inc
  • Biosearch SA
  • Faes Farma SA
  • Laboratorios Farmaceuticos Rovi SA
  • Laboratorio CIFGA SA
  • ALK-Abello AS
  • Laboratorios Richmond SACIF
  • GSK plc
  • Sucampo Pharmaceuticals Inc
  • Esteve Pharmaceuticals SA